Servier is ranked 1st for patient centricity,
information sharing, integrity, services 'beyond the pill',
engagement and communication and overall familiarity in the
industry
BOSTON, May 14, 2024
/PRNewswire/ -- Servier, a leader in oncology committed to
delivering transformative therapies to patients, is No. 1 in six
categories, among 37 companies featured in PatientView's 2023-2024
Corporate Reputation of Pharma survey. This annual survey includes
feedback from more than 300 patient organizations on their
perceptions, experiences and familiarity with pharmaceutical
companies.
"Patients are the North Star for everything we do at Servier.
Their experiences, stories, and insights guide our work and make us
better at what we do," said David K.
Lee, CEO of Servier Pharmaceuticals. "Our Patient Office,
who stays in lockstep with our patients and the groups that serve
them, and our unique governance model, allows us to be truly
patient centric across all corners of the organization. This year's
PatientView survey results reaffirm our continued commitment to
putting patients first and the critical role they play in every
aspect of our work, from drug development to education, outreach,
and access."
In the report, patient groups ranked Servier 1st for patient
centricity, information sharing, integrity, services 'beyond the
pill', engagement and communication and overall familiarity in the
industry.
"Understanding the increasing complexities and challenges
advocacy groups, patients and caregivers face enables us to meet
them where they are and provide needed tools and resources every
step of the way," said Wendy
Poage, VP of Servier's Patient Office. "Having the trust
of patient groups fuels our passion to be the best partner for
them, our patients and caregivers."
For more information on Servier Pharmaceuticals patient support
services, please visit servier.us/patient-support and
https://www.servierone.com/.
About the Corporate Reputation of Pharma – from the
Perspective of U.S.-Based Patient Groups
2023's 314 respondent U.S. patient groups specialized in a wide
range of therapy areas—the largest representation (113 respondent
patient groups) being cancer patient groups. The 314 stated that,
collectively, they had actively supported and served some 12
million US patients during 2023/24. The PatientView annual
Corporate Reputation of Pharma survey gives patient-advocacy groups
an opportunity to comment on, and assess, the pharma industry's
performance. Companies are ranked against their peers. The survey
results reinforce the dedication, commitment and hard work
companies invest internally to ensure engagement with patients and
advocacy groups is reflective of the patients they serve.
About Servier Pharmaceuticals
Servier Pharmaceuticals LLC is a commercial-stage company with a
passion for innovation and improving the lives of patients, their
families and caregivers. As a privately held company, Servier has
the unique freedom to devote all of its time and energy towards
patients who require our treatments, care and innovation in areas
of unmet medical need.
As a leader in oncology, Servier is committed to finding
solutions that will address today's challenges. The company's
oncology portfolio includes innovative medicines designed to bring
more life-saving treatments to a greater number of patients, across
the entire spectrum of disease and in a variety of tumor types.
Servier has significantly accelerated its investment in
hard-to-treat cancers with more than 50% of its research and
development dedicated to delivering significant advances in areas
of high unmet need that may truly move the needle for our
patients.
Servier believes co-creation is fundamental to driving
innovation and is actively building alliances, acquisitions,
licensing deals and partnerships that bring solutions and
accelerate access to therapies. With the company's commercial
expertise, global reach, scientific expertise and commitment to
clinical excellence, Servier Pharmaceuticals is dedicated to
bringing the promise of tomorrow to the patients that we serve.
For more information: www.servier.us.
Press Contact:
Servier Pharmaceuticals (U.S.)
Erin Smith
Erin.Smith@servier.com
Disclosures
This release contains general information about the Servier
Group and its entities (hereinafter "Servier and its Affiliates")
and is intended for informational purposes only. The information is
thought to be reliable; however, Servier and its Affiliates make no
representation as to the accuracy or completeness of the
information contained herein or otherwise provided and accept no
responsibility or liability, in contract, in tort, in negligence,
or otherwise, should the information be found to be inaccurate or
incomplete in any respect.
Servier and its Affiliates are not acting as an advisor to the
recipient of this information, and the ultimate decision to proceed
with any transaction rests solely with the recipient of this
information. Therefore, prior to entering into any proposed
transaction, the recipient of this information should determine,
without reliance upon Servier or its Affiliates, the economic risks
and merits, as well as the legal, tax, and accounting
characterizations and consequences, of the transaction and that it
is able to assume these risks.
This statement also contains forward-looking statements that are
subject to varying levels of uncertainty and risk. Investigational
new drugs and indications are subject to further scientific and
medical review and regulatory approval. They are not approved for
use by the FDA.
Any reliance placed on this document is done entirely at the
risk of the person placing such reliance. The information contained
in this document is neither an offer to sell nor the solicitation
of an offer to enter into a transaction.
The content of this document is a summary only, is not complete,
and does not include all material information about Servier and its
Affiliates, including potential conflicts of interest.
To the maximum extent permitted by applicable laws and
regulations, Servier and its Affiliates disclaim all
representations, warranties, conditions and guarantees, whether
express, implied, statutory or of other kind, nor does it accept
any duty to any person, in connection with this document. Without
prejudice to the generality of the foregoing, Servier and its
Affiliates do not warrant or represent that the information or
opinions contained in this document is accurate or complete.
To the maximum extent permitted by applicable laws and
regulations, Servier and its Affiliates shall not be liable for any
loss, damage or expense whatsoever, whether direct or indirect,
howsoever arising, whether in contract, tort (including
negligence), strict liability or otherwise, for direct, indirect,
incidental, consequential, punitive or special damages arising out
of or in connection with this document, including (without
limitation) any course of action taken on the basis of the same.
The estimates, strategies, and views expressed in this document are
based upon past or current data and information and are subject to
change without notice.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/servier-ranks-1st-across-several-categories-in-2023-2024-patientview-us-corporate-reputation-survey-302144762.html
SOURCE Servier Pharmaceuticals